---
title: Diabetes Management
author: J. Austin Straley, DO
layout: post
chapter: 9
section: 01
lesson: 35
date: 2023-03-30
---


- 1) Insulin Sensitizers: Lower Glucose by their actions on the liver, muscle and adipose tissue
  - A) Biguanides
    - MOA: Increases hepatic AMPK, inhibits mitochondrial hepatic gluconeogenesis and lipogenesis, increases peripheral uptake
      - Reduces hepatic gluconeogenesis and glycogenolysis
    - Metformin (Glucophage)
      - 500mg once to twice daily or 850mg once daily
        - Double dose after 5-7 days if no GI SE
        - Max: 850mg BID or 1000mg BID, lower dose if GI SE
      - 1st line therapy for T2DM, works on the liver
        - Inhibits mGPD and Complex 1
      - Improves fasting and postprandial hyperglycemia and hypertriglyceridemia in obese w/DM w/o Weight gain
        - Decreases A1c by 0.7-1.5%
      - Potential ASCVD benefit
      - SE: Lactic Acidosis in renal/liver failure (alcohol misuse), diarrhea
        - 20% GI upset, nausea, vomiting, no hypoglycemia
          - 2/2 decreasing glucose absorption in the GI tract
        - B12 deficiency
        - Good for obese patients
      - CI: Acute Renal Failure, Liver Failure, Sepsis, GFR \<30
        - Stop 48hrs before being given contrast
  - B) Glitazones/Thiazolidinediones (TZD)
    - MOA: Bind PPPAR-gamma nuclear transcription regulator, agonists, sensitizing peripheral tissue to insulin and increasing adiponectin
    - Increased GLUT1 and GLUT4, decreased FFA, decreased hepatic glucose output, increase adiponectin, and decreased adipocyte resistance, no hypoglycemia
      - Works on muscle and adipose tissue
    - Used in combo with metformin = no hypoglycemia
      - Can reduce insulin dose up to 50%, but edema increases 10-15%
      - Receptors also found in the collecting tubule of the nephron and stimulate increased sodium resorption (similar to aldosterone)
        - May use spironolactone to treat
    - Rosiglitazone (Avandia)
      - SE: increase LDL (15%), total cholesterol, and HDL (10%), decrease FFA (8-15%), Angina or MI increase risk, edema
    - Pioglitazone (Actos)
      - Lowers TG (9%), and increases HDL (15%), edema
    - SE: Weight gain, fluid retention and CHF, Hepatotoxic
    - CI: NYHA Class III/IV, Liver dysfunction
      - Black box for HF increased risk
      - Generally, not used in CKD
- 2) Secretagogues: Stimulate insulin secretion by binding the sulfonylurea receptor
  - A) Sulfonylureas
    - MOA: Closes K+ channels in pancreatic B cell membrane, causing the cell to depolarize, releasing insulin via increased Ca2+ influx
    - 1st Gen:
      - SE: Disulfram-like effects (Hyponatremia, flushing)
      - Chlorpropamide
      - Tolbutamide
      - Tolazamide
    - 2nd Gen:
      - 100x more potent, use in caution with CVD
        - Skip dose if pt too sick to eat (must be taken with meals, heavy sugar beverages, soda, juice, sweet tea)
      - Glimepiride (Amaryl)
      - Glipizide (Glucotrol)
        - CI: Liver failure
      - Glyburide (Diabeta)
        - CI: Liver disease, CKD
    - SE: Hypoglycemia (especially on an empty stomach), weight gain
    - Sulfonylurea poisoning
      - Treatment
        - Excessive amounts of Dextrose
        - Severe: Octreotide
  - B) Meglitinide analogs
    - MOA: Similar to Sulfonylureas, different binding site on Beta cell membrane
      - Take prior to meals
      - No sulfur moiety, no disulfram reaction
    - Repaglinide (Prandin)
      - SE: Hypoglycemia (worse with renal failure), WT gain
    - Nateglinide (Starlix)
      - D-Phenylalanine Derivative
      - Reduced postprandial risk in BP like Repaglinide
      - SE: Hypoglycemia (worse with renal failure), Wt gain
- 3) Secretagogues: Mimic incretin effect or prolong incretin action
  - A) Glucagon-like peptide 1 (GLP1) receptor agonists
    - MOA: Increase glucose dependent insulin secretion, decreases glucagon release, delays gastric emptying, increases satiety
      - Mimic incretins
      - More potent than DPP-4 Inhibitors
      - Decrease food intake, increase insulin, decrease glucagon, decrease gastric emptying
      - Associated with weight loss
      - Now preferred over insulin for most patients when injectable therapy is indicated
    - Dulaglutide (Trulicity)
      - 3rd most weight loss
    - Exenatide (Byetta, Bydureon)
      - CI: GFR \<30
    - Liraglutide (Victoza)
      - 6mg subq once daily for a week, then 1.2mg daily
        - 340B @ CAMC
      - 2nd most weight loss
      - LEADER Trial
        - Has FDA indication for ASCVD benefit
        - Decreased CV death by 22%, ACM by 15%
      - Has shown CKD benefit
    - Lixenatide
      - Least weight loss
      - Reduces CV mortality, may reduce CKD
    - Semaglutide (Rybelsus, Ozempic)
      - Ozempic: 0.25mg weekly for 4 weeks, then 0.5mg weekly up to 2mg weekly
      - Rybelsus: 3mg oral tablet, once daily
        - Only oral GLP-1 available
      - Most weight loss of group
    - SE: Weight loss, Nausea/Vomiting, pancreatitis, weight loss
      - Lower risk of hypoglycemia, decrease CVD/MI/Stroke, decrease progression of albuminuria
      - Black box warning of increased risk of thyroid C-cell tumors
    - RCI: History of Pancreatitis
  - B) DPP4 Inhibitors
    - MOA: Inhibits DPP-4 enzyme that deactivates GLP-1
      - Block the degradation of GLP-1 and GIP, thereby increasing insulin
      - Can't be used with GLP-1s
      - Once daily, few SE
    - Linagliptin (Tradjenta)
      - No dose adjustment for renal failure
    - Saxagliptin (Onglyza)
      - Increased risk of HF (only one in class)
    - Sitagliptin (Januvia)
    - Alogliptin
      - Increased risk of HF (not used)
    - SE: weight neutral, mild urinary or respiratory infections, nasopharyngitis
      - Potential increased risk of HF, joint pain, increased risk of pancreatitis
- 4) Slow intestinal absorption of glucose
  - A) Alpha-glucosidase inhibitors
    - MOA: Inhibits intestinal brush-border alpha-glucosidases, decreasing disaccharide absorption
      - Delayed carbohydrate hydrolysis and glucose absorption in the SI, increasing absorption in the large intesine
      - Decreases postprandial hyperglycemia
    - Acarbose (Precose)
      - Decreases postprandial hyperglycemia by 30-50%, decrease A1c by 0.5-1%, flatulence in 20-30%, abdominal pain
      - 3 times daily
      - Decreases intestinal CHO absorption
    - Miglitol (Glyset)
    - CI: Decreased renal function
    - SE: Diarrhea, Flatulence
- 5) Inhibit reabsorption of filtered glucose in the kidney
  - A) Sodium glucose co-transporter 2 inhibitors (SGLT2 Inhibitors)
    - MOA: Blocks reabsorption of glucose in proximal convoluted tubule
      - Causes glucosuria, weight loss is common
      - Causes osmotic diuresis, decreasing BP
      - Decreases progression of renal disease, Decreases CVD and MI risk if ASCVD
        - May improve CKD, still do not use if GFR \<30
    - Canagliflozin (Invokana)
      - Has shown CKD benefit, decreased CV death by 38%, ACM by 32%, HF hospitalization by 35%
      - EMPA-REG Outcome Trail
    - Dapagliflozin (Farxiga)
      - Has shown CKD benefit
    - Empagliflozin (Jardiance)
      - Has shown CKD benefit
      - Has FDA indication for ASCVD benefit, improving HF outcomes
      - EMPEROR Trials
        - HFpEF: Improved outcomes/Hospitalizations/QOL, Not mortality, reduced instance of hyperkalemia
        - HFrEF: Improved outcomes/Hospitalizations, improved eGFR, reduced instance of hyperkalemia
    - Ertugliflozin (Steglatro)
    - Check Cr prior to initiation
    - Indication: Type 2 DM or ASCVD (or give GLP-1) with metformin
      - Careful in amputation, severe PVD, neuropathy, diabetic foot ulcers
    - SE: Increases glucosuria, weight loss, UTIs, Genital infections, vaginal yeast infections, hyperkalemia, dehydration, orthostatic hypotension, Fournier's gangrene, Triple risk of DKA (Euglycemic DKA), risk of lower limb infection/ulceration/amputations
    - Hold for 24hrs prior to surgery or extreme sports
    - Decreases risk of MI, stroke, CVD death
- 6) Glucagon suppression and slowing gastric emptying
  - A) Amylin Analogs
    - Pramlintide (Symlin)
      - Delays gastric emptying and decreases glucagon
      - SE: hypoglycemia (always given with insulin), nausea/V
- 7) Other
  - Aldose Reductase Inhibitors
    - Epalrestat
  - Colesevelam (Welchol)
  - Bromocriptine (Cycloset)
  - Sitagliptin/Metformin (Janumet)

Insulin Preparations

- Fast Acting:
  - Lispro (Humalog), Aspart (Novolog), Glulisine (Apidra)
  - Peak: 0.5-1.5 hours
  - Duration: 3-5 hours
  - Peak coincides with food peak
- Short Acting:
  - Regular Insulin (Humulin R, Novolin R)
  - Peak: 2-4 hours
  - Duration: 5-8 hours
  - Peak may follow food peak
- Intermediate Acting:
  - NPH Insulin (Humulin N, Novolin N)
  - Peak: 4-12 hours
  - Duration: 14+ hours
- Long Acting:
  - Detemir (Levemir)
    - Peak: 4-9 hours
    - Duration: 12-24 hours
    - May require BID administration
  - Glargine (Lantus)
    - Peak: None
    - Duration: 14+ hours
    - Peakless effect less likely to cause hypoglycemia
    - Formulations with higher concentrations of glargine (300 vs 100u/mL) have longer duration (30+ hours)
- Ultra-Long Acting:
  - Degludec (Tresiba)
    - Peak: None
    - Duration: 42+ hours
    - Formation of a soluble hexamer at the injection site
- Sliding Scale
  - No basal insulin given, only reactively
  - Good with Basal-Bolus patient with Sliding scale on top prn